雄激素与卵巢储备功能减退:从基础科学到临床实施的漫长道路——一项全面系统综述与荟萃分析
本综述系统评价了雄激素(脱氢表雄酮/睾酮)对比安慰剂或无治疗对卵巢储备功能减退和/或卵巢低反应患者卵巢反应及妊娠结局的影响。荟萃分析显示脱氢表雄酮 priming 无显著差异,而睾酮预处理可能改善卵巢反应和妊娠结局,但证据质量低至中等,结果需谨慎解读。
要点
- 脱氢表雄酮 priming 对比安慰剂或无治疗,获卵数、成熟卵数、临床妊娠率、活产率和流产率均无显著差异。
- 睾酮预处理获卵数更高(均差0.94,95%CI 0.46-1.42),临床妊娠率更高(RR 2.07,95%CI 1.33-3.20),活产率更高(RR 2.09,95%CI 1.11-3.95)。
- 作者认为睾酮预处理可能有益,但证据质量低至中等,结果需谨慎解读。
核心结论
- 脱氢表雄酮对辅助生殖技术结局无明确效果,但睾酮预处理对卵巢反应和妊娠结局可能有益。
- 结果需谨慎解读,因现有证据质量低至中等。
研究设计与样本
- 本综述纳入比较使用雄激素(脱氢表雄酮和睾酮)的体外受精方案与常规体外受精刺激方案的随机对照试验。
- 检索MEDLINE、Embase、Cochrane Library、Cochrane Central Register of Controlled Trials、Scopus、ClinicalTrials.gov、ISRCTN registry和世界卫生组织国际临床试验注册平台,截至2021年9月。
- 采用修订版Cochrane随机试验偏倚风险工具(RoB 2)评估质量,荟萃分析使用随机效应模型,结果基于意向性分析解读,使用风险比和95%置信区间。
主要发现
- 脱氢表雄酮 priming 对比安慰剂或无治疗:获卵数均差0.76(95%CI -0.35至1.88),成熟卵数均差0.25(95%CI -0.27至0.76),临床妊娠率RR 1.17(95%CI 0.87-1.57),活产率RR 0.97(95%CI 0.47-2.01),流产率RR 0.80(95%CI 0.29-2.22),均无显著差异。
- 睾酮预处理对比对照:获卵数均差0.94(95%CI 0.46-1.42),临床妊娠率RR 2.07(95%CI 1.33-3.20),活产率RR 2.09(95%CI 1.11-3.95),均更高。
关键数值与推荐
- 纳入标准:比较使用雄激素(脱氢表雄酮和睾酮)的体外受精方案与常规体外受精刺激方案的随机对照试验,人群为卵巢储备功能减退和/或卵巢低反应患者。
- 结局指标包括卵巢反应和/或妊娠结局。
临床怎么用
- 作者认为睾酮预处理对卵巢反应和妊娠结局可能有益,但证据质量低至中等,结果需谨慎解读。
- 脱氢表雄酮对辅助生殖技术结局无明确效果。
局限性
- 现有证据质量低至中等。
- 结果应谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to present a narrative review regarding androgen production, androgens' role in folliculogenesis, and the available therapeutic approaches for androgen supplementation, and to perform a systematic review and meta-analysis regarding the impact of androgens (dehydroepiandrosterone/testosterone) compared with placebo or no treatment on ovarian response and pregnancy outcomes in patients with diminished ovarian reserve and/or poor ovarian responders. DATA SOURCES: An electronic search of MEDLINE, Embase, Cochrane Library, Cochrane Central Register of Controlled Trials, Scopus, ClinicalTrials.gov, the ISRCTN registry, and the World Health Organization International Clinical Trials Registry, was conducted for studies published until September 2021. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials that compared ovarian response and/or pregnancy outcomes between the different in vitro fertilization protocols using androgens (ie, dehydroepiandrosterone and testosterone) and conventional in vitro fertilization stimulation in patients with diminished ovarian reserve and/or poor ovarian responders were included. METHODS: The quality of each study was evaluated with the revised Cochrane risk-of-bias tool for randomized trials (RoB 2). The meta-analysis used random-effects models. All results were interpreted on the basis of intention-to-treat analysis (defined as the inclusion of all randomized patients in the denominator). Risk ratios and 95% confidence intervals were used and combined for meta-analysis. RESULTS: No significant differences were found regarding the number of oocytes retrieved (mean difference, 0.76; 95% confidence interval, -0.35 to 1.88), mature oocytes retrieved (mean difference, 0.25; 95% confidence interval, -0.27 to 0.76), clinical pregnancy rate (risk ratio, 1.17; 95% confidence interval, 0.87-1.57), live-birth rate (risk ratio, 0.97; 95% confidence interval, 0.47-2.01), or miscarriage rate (risk ratio, 0.80; 95% confidence interval, 0.29-2.22) when dehydroepiandrosterone priming was compared with placebo or no treatment. Testosterone pretreatment yielded a higher number of oocytes retrieved (mean difference, 0.94; 95% confidence interval, 0.46-1.42), a higher clinical pregnancy rate (risk ratio, 2.07; 95% confidence interval, 1.33-3.20), and higher live-birth rate (risk ratio, 2.09; 95% confidence interval, 1.11-3.95). CONCLUSION: Although dehydroepiandrosterone did not present a clear effect on outcomes of assisted reproductive techniques, we found a potentially beneficial effect of testosterone priming on ovarian response and pregnancy outcomes. However, results should be interpreted with caution, taking into account the low to moderate quality of the available evidence.
引用
- Neves AR, Montoya-Botero P, Polyzos NP, et al. Androgens and diminished ovarian reserve: the long road from basic science to clinical implementation. A comprehensive and systematic review with meta-analysis. Am J Obstet Gynecol. 2022. PMID: 35364061. doi:10.1016/j.ajog.2022.03.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。